At the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Pierluigi Porcu from Sidney Kimmel Cancer Center, Philadelphia, PA, describes the MAVORIC trial (NCT01728805) investigating the efficacy of vorinostat with the novel monoclonal antibody mogamulizumab in patients with refractory or relapsed cutaneous T-cell lyphoma (CTCL). Dr Pierluigi shares the trial design and highlights that further research is needed in order to tackle the unmet needs of CTCL.
MAVORIC trial: mogamulizumab for R/R CTCL
